Two key growth drivers for the U.S. preimplantation genetic testing market include advancements in genetic testing technologies, such as Next-Generation Sequencing (NGS) and Microarray, which allow for more accurate and comprehensive genetic analysis of embryos, and the growing prevalence of genetic disorders among couples, leading to increased demand for preimplantation genetic testing services.
In terms of segment analysis, the U.S. preimplantation genetic testing market can be divided into technology type (NGS, Microarray, others), test type (aneuploidy screening, single-gene disorder screening, chromosomal translocation screening, others), application (embryo testing, newborn screening, others), and end-user (fertility clinics, hospitals, research centers).
The competitive landscape of the U.S. preimplantation genetic testing market is characterized by the presence of several key players, such as Illumina, Inc., Thermo Fisher Scientific, Inc., PerkinElmer, Inc., Agilent Technologies, Inc., and CooperSurgical, Inc. These companies are investing in research and development activities to improve their product offerings and expand their market presence. Additionally, partnerships, collaborations, and strategic acquisitions are common strategies adopted by players in the market to enhance their competitive position.